Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC2277468545;68546;68547 chr2:178578620;178578619;178578618chr2:179443347;179443346;179443345
N2AB2113363622;63623;63624 chr2:178578620;178578619;178578618chr2:179443347;179443346;179443345
N2A2020660841;60842;60843 chr2:178578620;178578619;178578618chr2:179443347;179443346;179443345
N2B1370941350;41351;41352 chr2:178578620;178578619;178578618chr2:179443347;179443346;179443345
Novex-11383441725;41726;41727 chr2:178578620;178578619;178578618chr2:179443347;179443346;179443345
Novex-21390141926;41927;41928 chr2:178578620;178578619;178578618chr2:179443347;179443346;179443345
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: P
  • RefSeq wild type transcript codon: CCA
  • RefSeq wild type template codon: GGT
  • Domain: Fn3-53
  • Domain position: 32
  • Structural Position: 34
  • Q(SASA): 0.6513
  • Predicted PPI site: I

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
P/L rs886042240 -0.144 1.0 N 0.681 0.514 0.684920834152 gnomAD-2.1.1 4.08E-06 None None None None I None 0 0 None 0 0 None 3.35E-05 None 0 0 0
P/L rs886042240 -0.144 1.0 N 0.681 0.514 0.684920834152 gnomAD-4.0.0 1.59854E-06 None None None None I None 0 0 None 0 0 None 0 0 0 0 3.03693E-05

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
P/A 0.0927 likely_benign 0.0856 benign -0.526 Destabilizing 1.0 D 0.649 neutral N 0.471194655 None None I
P/C 0.5899 likely_pathogenic 0.5671 pathogenic -0.66 Destabilizing 1.0 D 0.636 neutral None None None None I
P/D 0.5607 ambiguous 0.6081 pathogenic -0.08 Destabilizing 1.0 D 0.683 prob.neutral None None None None I
P/E 0.3491 ambiguous 0.388 ambiguous -0.188 Destabilizing 1.0 D 0.694 prob.neutral None None None None I
P/F 0.5991 likely_pathogenic 0.5765 pathogenic -0.727 Destabilizing 1.0 D 0.578 neutral None None None None I
P/G 0.4342 ambiguous 0.4182 ambiguous -0.667 Destabilizing 1.0 D 0.728 prob.delet. None None None None I
P/H 0.2717 likely_benign 0.2812 benign -0.238 Destabilizing 1.0 D 0.602 neutral None None None None I
P/I 0.3275 likely_benign 0.3108 benign -0.305 Destabilizing 1.0 D 0.638 neutral None None None None I
P/K 0.3664 ambiguous 0.41 ambiguous -0.353 Destabilizing 1.0 D 0.683 prob.neutral None None None None I
P/L 0.1487 likely_benign 0.1409 benign -0.305 Destabilizing 1.0 D 0.681 prob.neutral N 0.505316478 None None I
P/M 0.3205 likely_benign 0.2964 benign -0.31 Destabilizing 1.0 D 0.604 neutral None None None None I
P/N 0.4017 ambiguous 0.3853 ambiguous -0.12 Destabilizing 1.0 D 0.671 neutral None None None None I
P/Q 0.1808 likely_benign 0.1878 benign -0.354 Destabilizing 1.0 D 0.652 neutral N 0.490135057 None None I
P/R 0.2616 likely_benign 0.2981 benign 0.131 Stabilizing 1.0 D 0.659 neutral N 0.47674129 None None I
P/S 0.1712 likely_benign 0.1596 benign -0.54 Destabilizing 1.0 D 0.714 prob.delet. N 0.485184306 None None I
P/T 0.1398 likely_benign 0.1333 benign -0.541 Destabilizing 1.0 D 0.699 prob.neutral N 0.483298202 None None I
P/V 0.2093 likely_benign 0.1976 benign -0.343 Destabilizing 1.0 D 0.691 prob.neutral None None None None I
P/W 0.7749 likely_pathogenic 0.7825 pathogenic -0.791 Destabilizing 1.0 D 0.643 neutral None None None None I
P/Y 0.5667 likely_pathogenic 0.5672 pathogenic -0.482 Destabilizing 1.0 D 0.587 neutral None None None None I

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.